Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Capricor Therapeutics, Inc. (CAPR : NSDQ)
 
 • Company Description   
Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California.

Number of Employees: 48

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.06 Daily Weekly Monthly
20 Day Moving Average: 100,364 shares
Shares Outstanding: 24.32 (millions)
Market Capitalization: $74.43 (millions)
Beta: 5.35
52 Week High: $6.22
52 Week Low: $2.56
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.99% 1.53%
12 Week -33.33% -27.95%
Year To Date 4.44% 23.70%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
10865 Road to the Cure Suite 150
-
San Diego,CA 92121
USA
ph: 310-358-3200
fax: 415-875-7075
jallaire@lifesciadvisors.com http://www.capricor.com
 
 • General Corporate Information   
Officers
Linda Marban - Chief Executive Officer and Director
Frank Litvack - Executive Chairman and Director
Anthony J. Bergmann - Chief Financial Officer
Earl M. Collier - Director
Louis V. Manzo - Director

Peer Information
Capricor Therapeutics, Inc. (BJCT)
Capricor Therapeutics, Inc. (CADMQ)
Capricor Therapeutics, Inc. (APNO)
Capricor Therapeutics, Inc. (UPDC)
Capricor Therapeutics, Inc. (IMTIQ)
Capricor Therapeutics, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 14070B309
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 24.32
Most Recent Split Date: 6.00 (0.10:1)
Beta: 5.35
Market Capitalization: $74.43 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.10 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.02
Price/Cash Flow: -
Price / Sales: 232.60
EPS Growth
vs. Year Ago Period: -39.13%
vs. Previous Quarter: -23.08%
Sales Growth
vs. Year Ago Period: 308.00%
vs. Previous Quarter: 397.56%
ROE
03/31/22 - -71.96
12/31/21 - -58.10
09/30/21 - -53.48
ROA
03/31/22 - -47.95
12/31/21 - -47.70
09/30/21 - -44.69
Current Ratio
03/31/22 - 4.16
12/31/21 - 8.82
09/30/21 - 13.82
Quick Ratio
03/31/22 - 4.16
12/31/21 - 8.82
09/30/21 - 13.82
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -11,122.06
12/31/21 - -8,172.65
09/30/21 - -5,943.90
Book Value
03/31/22 - 1.01
12/31/21 - 1.30
09/30/21 - 1.60
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©